ALVOAlvotech
Price
-27%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growth steady, the market undecided.
We are a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Our mission is to improve the health and quality of life of patients around the world by broadening the availability and accessibility of proven treatments for various diseases.
In the company’s own words · 20-F filed Mar 31, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Alvotech (ALVO) reported revenue of $280M in H2 2025 (quarter ended Dec 31, 2025), up 294% from the same quarter a year earlier. That came with a gross margin of 66% and net loss of $114M. For the full year FY2025, revenue was $586M (+20% year on year) and net income $28M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #26 of 41 by RyuScore